199 related articles for article (PubMed ID: 32213088)
1. Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions.
Price KAR; Nichols AC; Shen CJ; Rammal A; Lang P; Palma DA; Rosenberg AJ; Chera BS; Agrawal N
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-13. PubMed ID: 32213088
[TBL] [Abstract][Full Text] [Related]
2. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial.
Nichols AC; Lang P; Prisman E; Berthelet E; Tran E; Hamilton S; Wu J; Fung K; de Almeida JR; Bayley A; Goldstein DP; Eskander A; Husain Z; Bahig H; Christopoulous A; Hier M; Sultanem K; Richardson K; Mlynarek A; Krishnan S; Le H; Yoo J; MacNeil SD; Mendez A; Winquist E; Read N; Venkatesan V; Kuruvilla S; Warner A; Mitchell S; Corsten M; Rajaraman M; Johnson-Obaseki S; Eapen L; Odell M; Chandarana S; Banerjee R; Dort J; Matthews TW; Hart R; Kerr P; Dowthwaite S; Gupta M; Zhang H; Wright J; Parker C; Wehrli B; Kwan K; Theurer J; Palma DA
BMC Cancer; 2020 Feb; 20(1):125. PubMed ID: 32059705
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.
Rosenberg AJ; Vokes EE
Oncologist; 2021 Jan; 26(1):40-48. PubMed ID: 32864799
[TBL] [Abstract][Full Text] [Related]
4. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment.
Rosenberg AJ; Izumchenko E; Pearson A; Gooi Z; Blair E; Karrison T; Juloori A; Ginat D; Cipriani N; Lingen M; Sloane H; Edelstein DL; Keyser K; Fredebohm J; Holtrup F; Jones FS; Haraf D; Agrawal N; Vokes EE
BMC Cancer; 2022 Jan; 22(1):17. PubMed ID: 34980038
[TBL] [Abstract][Full Text] [Related]
5. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
Patel RR; Ludmir EB; Augustyn A; Zaorsky NG; Lehrer EJ; Ryali R; Trifiletti DM; Adeberg S; Amini A; Verma V
Oral Oncol; 2020 Apr; 103():104608. PubMed ID: 32163853
[TBL] [Abstract][Full Text] [Related]
6. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?
Wirth LJ; Burtness B; Nathan CO; Grégoire V; Richmon J
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():364-372. PubMed ID: 31099643
[TBL] [Abstract][Full Text] [Related]
7. De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
Petar S; Marko S; Ivica L
Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4599-4603. PubMed ID: 33599841
[TBL] [Abstract][Full Text] [Related]
8. Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus.
Geiger JL; Ku JA
Curr Treat Options Oncol; 2019 Feb; 20(3):20. PubMed ID: 30771020
[TBL] [Abstract][Full Text] [Related]
9. HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise.
Zakeri K; Dunn L; Lee N
J Surg Oncol; 2021 Nov; 124(6):962-966. PubMed ID: 34595766
[TBL] [Abstract][Full Text] [Related]
10. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
Gabani P; Lin AJ; Barnes J; Oppelt P; Adkins DR; Rich JT; Zevallos JP; Daly MD; Gay HA; Thorstad WL
Radiother Oncol; 2019 May; 134():81-88. PubMed ID: 31005228
[TBL] [Abstract][Full Text] [Related]
12. Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base.
Cheraghlou S; Yu PK; Otremba MD; Park HS; Bhatia A; Zogg CK; Mehra S; Yarbrough WG; Judson BL
Cancer; 2018 Feb; 124(4):717-726. PubMed ID: 29243245
[TBL] [Abstract][Full Text] [Related]
13. Treatment de-escalation for HPV+ oropharyngeal cancer: A systematic review and meta-analysis.
Petrelli F; Luciani A; Ghidini A; Cherri S; Gamba P; Maddalo M; Bossi P; Zaniboni A
Head Neck; 2022 May; 44(5):1255-1266. PubMed ID: 35238114
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.
Suton P; Skelin M; Rakusic Z; Dokuzovic S; Luksic I
Eur Arch Otorhinolaryngol; 2019 May; 276(5):1275-1281. PubMed ID: 30887169
[TBL] [Abstract][Full Text] [Related]
15. De-escalation treatment of human papillomavirus-positive oropharyngeal squamous cell carcinoma: an evidence-based review for the locally advanced disease.
Stock GT; Bonadio RRCC; de Castro G
Curr Opin Oncol; 2018 May; 30(3):146-151. PubMed ID: 29474271
[TBL] [Abstract][Full Text] [Related]
16. [De-escalation concepts for chemoradiotherapy of HPV-positive oropharyngeal carcinomas: pros and cons].
Rühle A; Nicolay NH
HNO; 2021 Apr; 69(4):278-284. PubMed ID: 33048200
[TBL] [Abstract][Full Text] [Related]
17. Rethinking treatment paradigms: Neoadjuvant therapy and de-escalation strategies in HPV-positive head and neck cancer.
Bouassaly J; Karimi N; Kowalski LP; Sultanem K; Alaoui-Jamali M; Mlynarek A; Mascarella M; Hier M; Sadeghi N; da Silva SD
Crit Rev Oncol Hematol; 2024 Apr; 196():104326. PubMed ID: 38479584
[TBL] [Abstract][Full Text] [Related]
18. [Treatment de-intensification strategies for HPV-driven oropharyngeal cancer: A short review].
Lahmamssi C; Guy JB; Benchekroun N; Bouchbika Z; Taoufik N; Jouhadi H; Sahraoui S; Benider A; Ben Mrad M; Jmour O; Bousarsar A; Lan ML; Lei Q; Benna M; Moslemi D; Vallard A; Magné N
Cancer Radiother; 2020 Jun; 24(3):258-266. PubMed ID: 32229067
[TBL] [Abstract][Full Text] [Related]
19. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
Rosenberg AJ; Agrawal N; Pearson A; Gooi Z; Blair E; Cursio J; Juloori A; Ginat D; Howard A; Chin J; Kochanny S; Foster C; Cipriani N; Lingen M; Izumchenko E; Seiwert TY; Haraf D; Vokes EE
Oral Oncol; 2021 Nov; 122():105566. PubMed ID: 34662771
[TBL] [Abstract][Full Text] [Related]
20. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies.
Mehanna H; Rischin D; Wong SJ; Gregoire V; Ferris R; Waldron J; Le QT; Forster M; Gillison M; Laskar S; Tahara M; Psyrri A; Vermorken J; Porceddu S
J Clin Oncol; 2020 Aug; 38(22):2552-2557. PubMed ID: 32496903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
